Sun Pharmaceuticals Industries Limited
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
Products Offered
The company produces a comprehensive and diverse portfolio of generic and specialty medicines targeting wide spectrum of chronic and acute treatments. Its product portfolio includes generics, branded generics, specialty, difficult-to-make technology intensive products, anti-retrovirals, APIs and intermediates.[1] It offers medicines in all form of dosages i.e. injectables, sprays, ointments, creams, liquids, tablets and capsules.
Shareholding Pattern
-PUBLIC GROUP
-PROMOTER GROUP
Financial Summary
| Particulars | March 2022 | March 2023 | March 2024 |
| Sales | 38,654 | 43,886 | 48,497 |
| Sales Growth % | 15.39% | 13.53% | 10.51% |
| Expenses | 28,397 | 32,235 | 35,479 |
| Operating Profit | 10,258 | 11,650 | 13,018 |
| OPM % | 27% | 27% | 27% |
| Net Profit | 3,389 | 8,513 | 9,610 |
| EPS in Rs | 13.64 | 35.32 | 39.91 |
Synopsis of Financials
- Q2 FY25 Sales: ₹132,642 million, up 10.5% YoY and 5.9% QoQ.
- Material Costs: 20.3% of sales, improved due to better product mix.
- Staff Costs: 18.7% of sales.
- Other Expenses: 32.5% of sales, increased due to higher selling and distribution expenses.
- H1 FY25 Gross Sales: ₹257,887 million, growth of 8.4% YoY.
- Net Profit for H1: ₹58,758 million, up 24.5% YoY (adjusted for exceptional items)
Final Outlook
For Long-Term Investors:
The stock remains bullish, with key support at ₹1,745 offering a solid accumulation zone.
Long-term targets align with the 2.618 Fibonacci level at ₹2,630, making the stock a compelling investment.
For Short-Term Traders:
Watch for bullish confirmation near ₹1,745. A breakout above ₹1,900 with strong volume could signal an upward rally.
A bearish breakdown below ₹1,745 could trigger a decline to ₹1,600.
Sun Pharma remains India’s largest pharmaceutical company and ranks among the top globally.
Valuation metrics suggest the stock is trading at a premium, supported by strong earnings growth and market dominance.
Sun-Pharmaceuticals-Industries-Limited-PDF-Report